900175-09-9 Usage
Uses
Used in Pharmaceutical Research:
(2,4-DIFLUORO-5-METHYLPHENYL)BORONIC ACID is used as a building block for the production of various pharmaceuticals. Its ability to selectively bind to certain biological targets makes it a valuable component in the development of new drugs.
Used in Agrochemical Production:
(2,4-DIFLUORO-5-METHYLPHENYL)BORONIC ACID is also used as a building block in the production of agrochemicals, contributing to the development of effective and targeted pesticides and other agricultural products.
Used as a Catalyst in Chemical Reactions:
(2,4-DIFLUORO-5-METHYLPHENYL)BORONIC ACID is utilized as a catalyst in various chemical reactions, particularly in the formation of carbon-carbon bonds. This application aids in the synthesis of complex organic compounds and contributes to the advancement of material science.
Used in Organic Synthesis:
(2,4-DIFLUORO-5-METHYLPHENYL)BORONIC ACID is employed in organic synthesis, where its unique properties facilitate the creation of new organic compounds and materials for various applications across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 900175-09-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,0,1,7 and 5 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 900175-09:
(8*9)+(7*0)+(6*0)+(5*1)+(4*7)+(3*5)+(2*0)+(1*9)=129
129 % 10 = 9
So 900175-09-9 is a valid CAS Registry Number.
900175-09-9Relevant academic research and scientific papers
PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS
-
Page/Page column 165, (2008/06/13)
The present invention relates generally to phenylglycinamide derivatives that inhibit serine proteases. In particular it is directed to novel phenylglycinamide derivatives, and analogues thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.
